Andrew Nixon

Overview:

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Positions:

Professor in Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 1997

Wake Forest University

Grants:

Preclinical and Human Correlative Studies of a Novel Bruton Tyronsine Kinase Inhibitor in Pancreatic Cancer

Administered By
Medicine, Medical Oncology
Awarded By
Department of Defense
Role
Co Investigator
Start Date
End Date

Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer

Administered By
Biostatistics & Bioinformatics
Awarded By
Department of Defense
Role
Partnering PI
Start Date
End Date

(PQA5) 'Dose and Mechanisms of Exercise in Breast Cancer Prevention'

Administered By
Radiation Oncology
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity

Administered By
Medicine, Medical Oncology
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Regulation Of Cyclic Gmp Phosphodiesterase By Gz

Administered By
Pharmacology & Cancer Biology
Awarded By
National Institutes of Health
Role
PI-Fellow
Start Date
End Date

Publications:

Prognostic and Predictive Biomarkers in Metastatic Colorectal Cancer Patients Receiving Regorafenib.

Regorafenib is a tyrosine kinase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of chemotherapy-refractory metastatic colorectal cancer (mCRC) patients. Regorafenib inhibits signaling through multiple receptors associated with angiogenesis, metastasis, and tumor immunity. Here we report biomarker results from LCCC1029, a randomized, placebo controlled, phase II trial of chemotherapy ± regorafenib in second-line mCRC patients. A panel of 20 soluble protein biomarkers (termed the Angiome) was assessed in the plasma of 149 patients from the LCCC1029 trial both at baseline and along the treatment continuum. Baseline protein levels were analyzed for prognostic and predictive value for progression-free survival (PFS) and overall survival (OS). Changes in protein levels during treatment were analyzed for potential pharmacodynamic effects. Six markers (HGF, IL-6, PlGF, VEGF-R1, OPN, and IL-6R) were found to be prognostic for PFS. Nine markers (IL-6, TIMP-1, PlGF, VCAM-1, ICAM-1, OPN, TSP-2, HGF, and VEGF-R1) were prognostic for OS. Higher baseline levels of OPN (Pintx=0.0167), VCAM-1 (Pintx=0.0216), and PDGF-AA (Pintx=0.0435) appeared to predict for PFS benefit from regorafenib compared to placebo. VCAM-1 was also potentially predictive of OS benefit from regorafenib compared to placebo (Pintx=0.0124). On-treatment changes of six markers reflected potential on-target effect of regorafenib. Consistent results were observed in an Italian cohort where 105 late-stage mCRC patients received regorafenib monotherapy. The key findings of this study suggest that VCAM-1 may be a predictive biomarker for regorafenib benefit while multiple protein markers may be prognostic of outcome in mCRC patients.
Authors
Liu, Y; Lyu, J; Bell Burdett, K; Sibley, AB; Hatch, AJ; Starr, MD; Brady, JC; Hammond, K; Marmorino, F; Rossini, D; Goldberg, RM; Falcone, A; Cremolini, C; Owzar, K; Ivanova, A; Moore, DT; Lee, MS; Sanoff, HK; Innocenti, F; Nixon, AB
MLA Citation
Liu, Yingmiao, et al. “Prognostic and Predictive Biomarkers in Metastatic Colorectal Cancer Patients Receiving Regorafenib.Mol Cancer Ther, Aug. 2020. Pubmed, doi:10.1158/1535-7163.MCT-20-0249.
URI
https://scholars.duke.edu/individual/pub1453716
PMID
32747417
Source
pubmed
Published In
Mol Cancer Ther
Published Date
DOI
10.1158/1535-7163.MCT-20-0249

A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA

Authors
Jia, J; Niedzwiecki, D; Arrowood, C; Garett-Mead, N; Nagy, R; Lanman, RB; Wright, J; Nixon, AB; Strickler, JH
URI
https://scholars.duke.edu/individual/pub1444228
Source
wos-lite
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date

MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE)

Authors
Kim, H; Halabi, S; Li, P; Mayhew, G; Simko, J; Nixon, A; Small, E; Rini, B; Morris, M; Taplin, M-E; George, D
MLA Citation
Kim, Hyung, et al. “MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE).” Journal of Urology, vol. 193, no. 4S, Ovid Technologies (Wolters Kluwer Health), 2015. Crossref, doi:10.1016/j.juro.2015.02.1543.
URI
https://scholars.duke.edu/individual/pub1438789
Source
crossref
Published In
The Journal of Urology
Volume
193
Published Date
DOI
10.1016/j.juro.2015.02.1543

COMPARISON OF ACCEPTOR AND DONOR SUBSTRATES IN THE COA-INDEPENDENT TRANSACYLASE (COA-IT) REACTION IN HUMAN NEUTROPHILS

Authors
NIXON, AB; GREENE, DG; WYKLE, RL
MLA Citation
NIXON, A. B., et al. “COMPARISON OF ACCEPTOR AND DONOR SUBSTRATES IN THE COA-INDEPENDENT TRANSACYLASE (COA-IT) REACTION IN HUMAN NEUTROPHILS.” Faseb Journal, vol. 9, no. 6, FEDERATION AMER SOC EXP BIOL, 1995, pp. A1307–A1307.
URI
https://scholars.duke.edu/individual/pub1438794
Source
wos
Published In
Faseb Journal
Volume
9
Published Date
Start Page
A1307
End Page
A1307

A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Authors
Arrillaga-Romany, I; Sahebjam, S; Picconi, D; Campian, J; Giglio, P; Drappatz, J; Aiken, R; Villano, J; Lee, E; Welch, M; Ellingson, B; Ney, D; Becker, K; Muzikansky, A; Das, B; Swisher, E; Nixon, A; Karlovich, C; Williams, PM; Ivy, SP; Batchelor, T; Gerstner, E
MLA Citation
Arrillaga-Romany, Isabel, et al. “A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA.” Neuro Oncology, vol. 21, OXFORD UNIV PRESS INC, 2019, pp. 27–27.
URI
https://scholars.duke.edu/individual/pub1438784
Source
wos
Published In
Neuro Oncology
Volume
21
Published Date
Start Page
27
End Page
27